Cargando…

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?

Detalles Bibliográficos
Autores principales:	Zhang, Zhenyang, Lin, Jiangbo, Kang, Mingqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139056/ https://www.ncbi.nlm.nih.gov/pubmed/32274192 http://dx.doi.org/10.21037/jtd.2019.11.38

Ejemplares similares

Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
por: Aguado, Carlos, et al.
Publicado: (2022)

Postoperative adjuvant therapy for resectable early non-small cell lung cancer: A protocol for a systematic review and meta-analysis
por: Chai, Tianci, et al.
Publicado: (2019)

Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)

Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)
por: Zhang, Zhenyang, et al.
Publicado: (2021)

Platinum versus immunotherapy for early resectable non-small cell lung cancer: A protocol for systematic review and meta analysis
por: Tong, Zhangwei, et al.
Publicado: (2020)

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Comments on “dynamic (18)F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer”
por: Wang, Shan‐Ying, et al.
Publicado: (2022)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
por: Qin, Kang, et al.
Publicado: (2020)

Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Xiang, Yi, et al.
Publicado: (2022)

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report
por: Yang, Jie, et al.
Publicado: (2021)

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
por: Wang, Shuai, et al.
Publicado: (2015)

The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
por: Zhao, Dan, et al.
Publicado: (2017)

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
por: Kang, Jin, et al.
Publicado: (2021)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Are TKIs favourable for the elderly with non-small-cell lung cancer?
por: Rossi, Sabrina, et al.
Publicado: (2016)

Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer
por: Ebinç, Senar, et al.
Publicado: (2023)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Wu, Yahua, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
por: Gogia, Ajay, et al.
Publicado: (2018)

Reply: Adjuvant chemoradiotherapy is no alternative to intensified neoadjuvant chemoradiotherapy for local and systemic control in patients with locally advanced rectal cancer
por: Klautke, G, et al.
Publicado: (2006)

Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Effect of closed vacuum aspiration technique on lung collapse time in thoracoscopic anatomical segmentectomy
por: Zhang, Zhenyang, et al.
Publicado: (2019)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review
por: Liu, Lian, et al.
Publicado: (2019)

Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2021)

Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients
por: Chen, Xueqin, et al.
Publicado: (2015)

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2020)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
por: Kepka, Lucyna, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study
por: Hong, Zhi-Nuan, et al.
Publicado: (2021)

Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
por: Guo, Hanfei, et al.
Publicado: (2021)

Long intergenic non‐coding RNA Linc00485 promotes lung cancer progression by modulating miR‐298/c‐Myc axis
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Lung autotransplantation for the treatment of locally advanced tumors
por: de Brito, João Marcelo Lopes Toscano, et al.
Publicado: (2021)

Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
por: Jung, Yun Duk, et al.
Publicado: (2017)

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023)

Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer
por: Lewis, Jennifer, et al.
Publicado: (2018)

Advanced non-small cell lung cancer associated with hemophagocytic syndrome in a cachectic patient
por: Asai, Nobuhiro, et al.
Publicado: (2012)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0v5c1orpgifvnf3qfbhc5sje3r